Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 11/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | CCKAR | P32238 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177281 | 0.90 | MEN1 (0.60) | CCKBRCCKARMEN1KMT2AALDH1A1 | |
| SCHEMBL641925 | 0.85 | LMNA (0.70) | CCKBRMEN1KMT2ALMNAALB | |
| SCHEMBL3186746 | 0.85 | MEN1 (0.57) | CCKBRCCKARMEN1KMT2ALMNA | |
| SCHEMBL2526769 | 0.82 | CCKBR (0.56) | CCKBRCCKARMEN1KMT2ALMNA | |
| SCHEMBL4703948 | 0.80 | LMNA (0.71) | MEN1KMT2ALMNAALB | |
| SCHEMBL4796036 | 0.79 | CCKBR (0.56) | CCKBRCCKARMEN1KMT2ALMNA | |
| SCHEMBL25253681 | 0.79 | CCKBR (0.59) | CCKBRCCKARMEN1KMT2ALMNA | |
| SCHEMBL25253683 | 0.79 | CCKBR (0.59) | CCKBRCCKARMEN1KMT2ALMNA | |
| SCHEMBL11831521 | 0.79 | MEN1 (0.62) | CCKBRCCKARMEN1KMT2AALDH1A1 | |
| Thiophene Carboxylic Acid SCHEMBL643248 | 0.78 | MEN1 (0.48) | CCKBRCCKARMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318427-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| US-20090318427-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-1928465-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | Arrow Therapeutics Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007034127-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318427-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | CNR1, GABRA6, SIGMAR1 | CCKBR 170/4885BRD4 482/4885CCKAR 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.